Regimen Education and Messaging in Diabetes (REMinD)

Sponsor
Northwestern University (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT03185741
Collaborator
Icahn School of Medicine at Mount Sinai (Other), Emory University (Other), Northwestern Memorial Hospital (Other)
750
2
3
54.8
375
6.8

Study Details

Study Description

Brief Summary

The investigators will leverage increasingly available technologies to impart a Universal Medication Schedule (UMS) in primary care to help patients living with diabetes safely use and adhere to complex drug regimens. The UMS standardizes the prescribing and dispensing of medicine by using health literacy principles and more explicit times to describe when to take medicine (morning, noon, evening, bedtime). This eliminates variability found in the way prescriptions are written by physicians and transcribed by pharmacists onto drug bottle labels. The proposed intervention will standardize prescribing within an electronic health record (EHR) so all medication orders include UMS prescription instructions ('sigs') and patients receive a medication information sheet with their after-visit summaries. Additionally, to help patients remember when to take prescribed medicines we will link unidirectional short message service (SMS) text reminders to the EHR, delivering medication reminders to patients around UMS intervals.

  1. Test the effectiveness of the UMS, and UMS + SMS text reminder strategies compared to usual care.

  2. Determine if the effects of these UMS strategies vary by patients' literacy skills and language.

  3. Using mixed methods, evaluate the fidelity of the two strategies and explore patient, staff, physician, and health system factors influencing the interventions.

  4. Assess the costs required to deliver either intervention from a health system perspective.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: UMS Strategy
  • Behavioral: SMS Text Messaging
N/A

Detailed Description

The investigators will leverage increasingly available technologies to impart a Universal Medication Schedule (UMS) in primary care to help patients living with diabetes safely use and adhere to complex drug regimens. The UMS standardizes the prescribing and dispensing of medicine by using health literacy principles and more explicit times to describe when to take medicine (morning, noon, evening, bedtime). This eliminates variability found in the way prescriptions are written by physicians and transcribed by pharmacists onto drug bottle labels. The proposed intervention will standardize prescribing within an electronic health record (EHR) so all medication orders include UMS prescription instructions ('sigs') and patients receive a medication information sheet with their after-visit summaries. Additionally, to help patients remember when to take prescribed medicines we will link unidirectional short message service (SMS) text reminders to the EHR, delivering medication reminders to patients around UMS intervals.

The investigators will conduct a 3-arm, multi-site trial to test the effectiveness of the UMS, and UMS + SMS text reminder strategies compared to usual care. The investigators will enroll a total of 900 English and Spanish-speaking patients with poorly controlled type 2 diabetes mellitus. Enrolled patients will complete follow-up interviews 3 and 6 months following their baseline interview.

The aims of the investigation are to:
  1. Test the effectiveness of the UMS, and UMS + SMS text reminder strategies compared to usual care.

  2. Determine if the effects of these UMS strategies vary by patients' literacy skills and language.

  3. Using mixed methods, evaluate the fidelity of the two strategies and explore patient, staff, physician, and health system factors influencing the interventions.

  4. Assess the costs required to deliver either intervention from a health system perspective.

Study Design

Study Type:
Interventional
Actual Enrollment :
750 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
EHR-based Universal Medication Schedule to Improve Adherence to Complex Regimens
Actual Study Start Date :
Jan 5, 2018
Actual Primary Completion Date :
Feb 2, 2022
Anticipated Study Completion Date :
Jul 30, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: UMS Strategy

Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions. These materials will be generated within the electronic health record. Prescription instructions will be adapted to the UMS format to establish four standard time intervals (morning, noon, evening, bedtime) for prescribing and dispensing of medicine. UMS instructions also use simplified text and numeric characters instead of words to detail dose. Single-page, plain language medication information sheets with important medication-related information following health literacy best practices.

Behavioral: UMS Strategy
Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.

Experimental: UMS Strategy + SMS Text Messaging

In addition to the components from the UMS strategy arm, patients will receive daily text message reminders for 6 months.

Behavioral: UMS Strategy
Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.

Behavioral: SMS Text Messaging
Patients will receive daily text message reminders about when to take medicines based on UMS intervals.

No Intervention: Usual Care

Patients of providers randomized to the usual care arm will receive their standard care

Outcome Measures

Primary Outcome Measures

  1. Medication adherence: Pill Count [6 months after baseline]

    Adherence will be measured for each prescription medication using an objective pill count of the number of pills within each prescription bottle.

Secondary Outcome Measures

  1. Medication adherence: 24-hour recall [6 months after baseline]

    Adherence will be measured for each prescription medication using self-report of how many pills and how often each medicine was taken over the last 24 hours

  2. Medication adherence: ASK-12 [6 months after baseline]

    Adherence will be measured by the ASK-12 Adherence Barrier Survey, a subjective assessment of general adherence behaviors and barriers to treatment adherence.

  3. Treatment knowledge [6 months after baseline]

    Identification of drug purpose

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Type 2 diabetes mellitus diagnosis

  2. Most recent hba1c value ≥7.5%.

  3. Seek care at participating general internal medicine practices in Chicago or New York City.

  4. English or Spanish speaking

  5. Take 5 or more prescription drugs for chronic conditions (including 1 study medication)

Exclusion Criteria:
  1. Severe uncorrectable vision or hearing impairment

  2. Cognitive impairment (≥2 errors on a 6-item dementia screening tool or a chart-documented diagnosis of dementia)

  3. Not primarily responsible for administering his/her medications

  4. Does not own a cell phone that can receive text messages

  5. Not comfortable receiving text messages

Contacts and Locations

Locations

Site City State Country Postal Code
1 Northwestern University Chicago Illinois United States 60611
2 Mount Sinai School of Medicine New York New York United States 10029

Sponsors and Collaborators

  • Northwestern University
  • Icahn School of Medicine at Mount Sinai
  • Emory University
  • Northwestern Memorial Hospital

Investigators

  • Principal Investigator: Michael Wolf, PhD MPH, Northwestern University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Michael S. Wolf, Professor, Northwestern University
ClinicalTrials.gov Identifier:
NCT03185741
Other Study ID Numbers:
  • R01NR015444
First Posted:
Jun 14, 2017
Last Update Posted:
Mar 3, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 3, 2022